Stock MNKD MANNKIND CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

News MannKind Corporation

Equities

MNKD

US56400P7069

Real-time Estimate Cboe BZX
Other stock markets
 01:00:18 2024-05-09 pm EDT 		5-day change 1st Jan Change
4.345 USD -1.25% Intraday chart for MannKind Corporation +0.57% +21.02%
May. 08 Earnings Flash (MNKD) MANNKIND Posts Q1 EPS $0.05 MT
May. 08 Earnings Flash (MNKD) MANNKIND Reports Q1 Revenue $66.3M, vs. Street Est of $60.6M MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
MannKind: Q1 Earnings Snapshot
AQ
Earnings Flash (MNKD) MANNKIND Posts Q1 EPS $0.05
MT
Earnings Flash (MNKD) MANNKIND Reports Q1 Revenue $66.3M, vs. Street Est of $60.6M
MT
MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update
AQ
MannKind Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
MannKind Receives FDA Fast Track Designation for its Potential Lung Disease Treatment
MT
MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
AQ
MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial Lung Disease
CI
MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024
AQ
MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases
AQ
MannKind Corporation to Proceed with Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases
CI
MannKind Gets FDA Approval to Begin Phase 3 Trial of Lung Disease Treatment
MT
MannKind Gets FDA Clearance for Clofazimine IND Application
DJ
MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease
AQ
MannKind Corporation Announces IND Clearance from U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial Lung Disease
CI
MannKind Repays Certain Debt Obligations
AQ
MannKind CFO Binder to Retire in April, Names New CFO
MT
MannKind Announces CFO Transition
AQ
MannKind Corporation Announces Chief Financial Officer Changes, Effective April 22, 2024
CI
MannKind Corporation Appoints Steven B. Binder as Executive Vice President, Special Projects
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MNKD Stock
  4. News MannKind Corporation
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW